"The U.S. Food and Drug Administration today approved the first generic versions of Aciphex (rabeprazole sodium) delayed-release tablets, used to treat gastroesophageal reflux disease (GERD) in adults and adolescents (ages 12 and up).
Kapidex Delayed Release Capsules
There have been no reports of significant overdose of KAPIDEX (dexlansoprazole delayed release capsules) . Multiple doses of KAPIDEX (dexlansoprazole delayed release capsules) 120 mg and a single dose of KAPIDEX (dexlansoprazole delayed release capsules) 300 mg did not result in death or other severe adverse events. Dexlansoprazole is not expected to be removed from the circulation by hemodialysis. If an overdose occurs, treatment should be symptomatic and supportive.
KAPIDEX (dexlansoprazole delayed release capsules) is contraindicated in patients with known hypersensitivity to any component of the formulation [see DESCRIPTION]. Hypersensitivity and anaphylaxis have been reported with KAPIDEX use [see ADVERSE REACTIONS].
Last reviewed on RxList: 4/14/2010
This monograph has been modified to include the generic and brand name in many instances.
Additional Kapidex Delayed Release Capsules Information
Report Problems to the Food and Drug Administration
Get the latest treatment options.